C07K 14/505
Erythropoietin [epo]
Official title: Erythropoietin [EPO]
C07K14/505 (Erythropoietin [epo]) appears on 708 US grants and 1,002 published applications in this corpus.
Search patents in C07K- Granted patents
- 708
- Published applications
- 1,002
- Assignees
- 330
- Inventors
- 1,257
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 8 | 0 |
| 1998 | 11 | 0 |
| 1999 | 20 | 0 |
| 2000 | 11 | 0 |
| 2001 | 10 | 3 |
| 2002 | 19 | 20 |
| 2003 | 17 | 35 |
| 2004 | 14 | 42 |
| 2005 | 11 | 49 |
| 2006 | 21 | 49 |
| 2007 | 34 | 38 |
| 2008 | 23 | 49 |
| 2009 | 27 | 62 |
| 2010 | 31 | 42 |
| 2011 | 33 | 47 |
| 2012 | 32 | 38 |
| 2013 | 22 | 34 |
| 2014 | 37 | 66 |
| 2015 | 40 | 61 |
| 2016 | 35 | 56 |
| 2017 | 32 | 41 |
| 2018 | 34 | 34 |
| 2019 | 31 | 36 |
| 2020 | 22 | 32 |
| 2021 | 21 | 35 |
| 2022 | 18 | 40 |
| 2023 | 19 | 36 |
| 2024 | 15 | 24 |
| 2025 | 18 | 20 |
| 2026 | 12 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of increasing an immune response to a cancer by administering an antibody which inhibits erythropoietin receptor activation8 Sep 2026US 12,729,240 B2ImmunEdge, Inc.
- Apparatus and a method for continuously harvesting a biological substance produced by a cultured cell11 Aug 2026US 12,703,846 B2Wuxi Biologics Ireland Limited
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Methods for making stable protein compositions14 Jul 2026US 12,679,865 B2Amgen Inc.
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Aav-epo for treating companion animals1 Oct 2026US 2026/0297149 A1The Trustees of the University of Pennsylvania
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Synthesis and structure of high potency rna therapeutics10 Sep 2026US 2026/0265769 A1Arcturus Therapeutics, Inc.
- Erythropoietin receptor compositions and methods of use thereof3 Sep 2026US 2026/0258144 A1ImmunEdge, Inc.
- Recombinant production of protein having xylosylated n-glycans2 Jul 2026US 2026/0184752 A1Expres2ion Biotechnologies ApS
Most cited
By later US patents
- Oligonucleotide mediated nucleic acid recombination400US 6,376,246 B1Maxygen, Inc. · 2002
- Modified peptides as therapeutic agents359US 6,660,843 B1Amgen Inc. · 2003
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- DNA sequences encoding erythropoietin349US 4,703,008 AKiren-Amgen, Inc. · 1987
- In vivo incorporation of unnatural amino acids304US 7,045,337 B2The Regents of the University of California · 2006